- You Are Here:
- Home
- Media Center
- News
- Current News
- Reata Expects to Double Staff by the End of 2020
Create an Account - Increase your productivity, customize your experience, and engage in information you care about.
The publicly-traded company will use the funds to register and commercialize medications for two rare genetic diseases in the U.S and across the globe.
Plano-based drug developer Reata Pharmaceuticals Inc. raised more than $505 million in a stock sale Monday to speed its transition from a clinical-stage biotech startup to a company that makes treatments for life-threatening diseases.